Sequence: EEV1-derived cyclic CPP + SV40 NLS (PKKKRKV); full sequence not disclosed
PMO (antisense oligonucleotide)
| Experiment Id | EXP001253 |
|---|---|
| Paper | The endosomal escape vehicle platform enhances delivery of oligonucleotides in preclinical models of |
| Peptide | EEV2 |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | |
| Rna Concentration | 2 µM (PMO equiv; LSR-labeled comparator study) |
| Mixing Ratio | |
| Formulation Format | covalent peptide–PMO conjugate |
| Formulation Components | EEV2-PMO654 (± lissamine rhodamine B label in uptake/EGFP assays) |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | HeLa EGFP-654 cells |
| Animal Model | |
| Administration Route | |
| Output Type | reporter expression |
| Output Value | ~19× higher EGFP fluorescence vs unconjugated PMO; ~9× vs EEV1-PMO654 (at 2 µM, LSR-labeled) |
| Output Units | |
| Output Notes | EGFP fluorescence by flow cytometry and microscopy; uptake quantified via LSR signal. |
| Toxicity Notes | |
| Curation Notes |